Cancer Biomarkers Market to Reach USD 47.25 Billion by 2029 as Precision Oncology and Early Cancer Detection Accelerate Demand

Cancer Biomarkers Market Overview

The Global Cancer Biomarkers Market was valued at USD 14.65 billion in 2022 and is projected to reach USD 47.25 billion by 2029, registering a CAGR of 18.25% during 2022–2029, according to Maximize Market Research. Cancer biomarkers are increasingly important in early cancer detection, diagnosis, disease-risk assessment, treatment selection, therapy monitoring, drug development, and personalized medicine. The increasing global burden of cancer, growing awareness of early diagnosis, and rapid advances in genomics, proteomics, and molecular diagnostics are creating strong opportunities for market expansion.

Technological progress in array technologies, proteomics, genomic analysis, and molecular testing is making the discovery and development of cancer biomarkers more efficient. The increasing adoption of companion diagnostics is another major growth opportunity because biomarkers can help identify patients who are most likely to respond to particular therapies. Pharmaceutical and biotechnology companies are also advancing biomarker candidates for oncology drug development, creating opportunities across diagnostics and therapeutic research. However, insufficient reimbursement for biomarker testing, high diagnostic costs, sample collection and storage requirements, and challenges associated with validating sensitivity, specificity, and reproducibility can restrict market expansion.

* Request Your Free Sample Copy: https://www.maximizemarketresearch.com/request-sample/83612/ 

U.S. Market Trends and Investment

The United States remains a major center for cancer biomarker development because of its advanced healthcare infrastructure, large research ecosystem, pharmaceutical industry, and growing adoption of precision oncology. In 2025, regulatory and commercial activity continued to strengthen the biomarker landscape. The FDA's Oncology Center of Excellence identified validation of liquid-biopsy and multiomic biomarkers as an important research priority, including biomarkers for treatment response and resistance. The FDA is also conducting research into circulating tumor DNA for minimal residual disease applications, while its 2025 research portfolio included AI-enabled biomarkers for predicting cancer-therapy-related cardiac dysfunction. These initiatives are supporting the development and validation of next-generation biomarkers and could accelerate their integration into clinical trials and personalized cancer treatment.

Market Segmentation: Breast Cancer and Diagnostics Lead

Based on Cancer Type, Breast Cancer accounted for the largest market share in 2022. The segment's dominance is supported by a large target population and increasing awareness of early cancer testing. The MMR report also identifies lung cancer as the fastest-growing cancer-type segment, driven by the development of diagnostic tests targeting biomarkers such as EGFR and BRAF mutations.

Based on Application, Diagnostics represented the primary revenue-generating segment. Increasing development of high-specificity and high-sensitivity biomarker-based oncology tests is supporting the segment's leadership. The growing acceptance of companion diagnostics and increasing interest in personalized medicine are expected to create further opportunities for biomarker-based testing.

Cancer Biomarkers Market Key Players:
1. Abbott Laboratories
2. F.Hoffmann-LA Roche Ltd.
3. QIAGEN
4. Thermo Fisher Scientific Inc.
5. Affymetrix Inc.
6. Illumina Inc.
7. Agilent Technologies
8. Merck & Co. Inc.
9. Hologic Inc.
10.Sino Biological Inc.
11.Becton, Dickinson and Company
12.PerkinElmer Inc.
13.Bristol-Myers Squibb
14.Bio-Rad Laboratories
15.Eli-Lilly and Company
16.Pfizer Inc.
17.GlaxoSmithKline Plc.
18.Novartis AG

Competitive Analysis

The key companies identified in the supplied MMR report are Abbott Laboratories, F. Hoffmann-La Roche Ltd., QIAGEN, Thermo Fisher Scientific Inc., and Affymetrix Inc., followed by Illumina Inc., Agilent Technologies, Merck & Co. Inc., Hologic Inc., Sino Biological Inc., Becton, Dickinson and Company, PerkinElmer Inc., Bristol-Myers Squibb, Bio-Rad Laboratories, Eli Lilly and Company, Pfizer, GlaxoSmithKline, and Novartis. The MMR report does not provide individual percentage market shares for these companies; therefore, specific company shares have not been estimated.

Abbott Laboratories is strengthening precision-oncology capabilities through molecular diagnostics and circulating tumor DNA technologies. In 2025, Abbott highlighted its growing precision-oncology portfolio, including the launch of its Oncodetect molecular residual disease test and continued development of liquid-biopsy applications. Such technologies can enable clinicians to identify molecular traces of cancer and support treatment monitoring.

F. Hoffmann-La Roche Ltd. continued significant investment in oncology diagnostics and digital pathology during 2025. Roche received FDA Breakthrough Device Designation for its AI-driven VENTANA TROP2 companion diagnostic for non-small cell lung cancer. The system combines immunohistochemistry with an AI-based digital pathology algorithm, demonstrating how artificial intelligence can improve biomarker assessment and patient selection.

QIAGEN continues to expand molecular testing capabilities for oncology and companion diagnostics. Its molecular-testing platforms support biomarker analysis used to guide targeted cancer therapies, while continued development of sample technologies and molecular assays can increase the accessibility of precision oncology.

Thermo Fisher Scientific Inc. is expanding its role in oncology through next-generation sequencing, molecular diagnostics, and comprehensive genomic profiling. The broader adoption of NGS-based biomarker testing is creating opportunities for identifying actionable genomic alterations and supporting personalized treatment decisions.

Affymetrix Inc. has contributed array-based technologies used in genomic and biomarker research. Although Affymetrix was acquired by Thermo Fisher Scientific, its technologies and intellectual property remain relevant to the development of genomic analysis workflows and biomarker discovery.

Regional Analysis: United States

The United States is the principal market within North America, while North America accounted for 42% of the global Cancer Biomarkers Market in 2022, according to MMR. The region's leadership is supported by a strong healthcare infrastructure, high investment in advanced diagnostic technologies, extensive cancer research, pharmaceutical development activity, and increasing use of biomarkers for tumor detection and monitoring.

Government-backed research and regulatory activity are also creating favorable conditions. The FDA is actively investigating liquid biopsy, ctDNA, multiomic biomarkers, and AI-enabled biomarker applications. In addition, biomarker-driven companion diagnostics are increasingly important for selecting patients for targeted oncology therapies. These developments can improve early detection, treatment personalization, and monitoring of therapeutic response. The supplied MMR report does not disclose a specific U.S. percentage of the global market, so no country-level share has been estimated.

Related Reports

Personalized LASIK Surgery Market https://www.maximizemarketresearch.com/market-report/personalized-lasik-surgery-market/230753/ 

Venous Stents Market https://www.maximizemarketresearch.com/market-report/venous-stents-market/231857/ 

Aspergillosis Market https://www.maximizemarketresearch.com/market-report/aspergillosis-market/233535/ 

Conclusion

The Cancer Biomarkers Market is positioned for strong expansion as oncology increasingly moves toward early detection, precision medicine, and biomarker-guided treatment. The combination of genomic technologies, liquid biopsy, proteomics, AI-enabled pathology, companion diagnostics, and molecular residual disease testing is creating substantial opportunities for healthcare and biotechnology companies. Breast cancer and diagnostic applications currently represent the leading areas identified by MMR, while emerging applications in lung cancer, ctDNA, and personalized medicine can provide additional growth opportunities. Continued investment in biomarker discovery, clinical validation, reimbursement frameworks, and affordable testing will be critical to translating technological advances into broader clinical adoption through 2029.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
📞 +91 9607365656
📧 sales@maximizemarketresearch.com